Εμφάνιση απλής εγγραφής

dc.creatorTsironi, E.en
dc.creatorGatselis, N.en
dc.creatorKotoula, M. G.en
dc.creatorZachou, K.en
dc.creatorPefkianaki, M.en
dc.creatorZacharaki, F.en
dc.creatorChatzoulis, D. Z.en
dc.creatorDalekos, G. N.en
dc.date.accessioned2015-11-23T10:51:56Z
dc.date.available2015-11-23T10:51:56Z
dc.date.issued2009
dc.identifier10.1186/1757-1626-2-159
dc.identifier.issn17571626
dc.identifier.urihttp://hdl.handle.net/11615/33987
dc.description.abstractIntroduction: Antiphospholipid syndrome is an autoimmune disorder characterized by either a history of vascular thrombosis (one or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ) or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The systemic features of the syndrome are characterized by large variability depending on the affected organ(s). Among them, neurological and behavioural disturbances, dermatological features as livedo reticularis and renal, ocular, liver or valvular heart manifestations have been reported in antiphospholipid syndrome patients. However, studies on the frequency and clinical presentation of the ocular manifestations as the prevailing (first) sign of antiphospholipid syndrome in patients suffering from "unexplained" ocular disease are missing. Herein, we present three cases suffering from unexplained ocular disease as first manifestation of antiphospholipid syndrome. Case presentation: All the three patients were referred to our department because of unexplained ocular features from the anterior or posterior segment and unexplained neuroophthalmologic symptoms. The first patient had bilateral retinal occlusive disease, the second and the third patient had unilateral nonarteritic anterior ischemic optic neuropathy with macular oedema. Moderate to high levels of antiphospholipid antibodies were detected in all of them at baseline as well as 6 to 12 weeks after initial testing confirming the presence of antiphospholipid antibodies. Anticoagulant treatment with acenocoumarol was instituted resulting in stabilization and/or improvement of ocular signs in all of them. Conclusion: Due to the important diagnostic and therapeutic implications of antiphospholipid syndrome, the possibility of ocular features as the first clinical manifestation of antiphospholipid syndrome should be kept in mind of the physicians particularly in patients with no evident risk factors for ocular disease. In this case, prompt anticoagulant treatment and close follow-up seem to be essential for vision salvation and stabilization. © 2009 Tsironi et al; licensee BioMed Central Ltd.en
dc.source.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-77953437708&partnerID=40&md5=365fdc392967693af86bba729eed38b0
dc.subjectacenocoumarolen
dc.subjectphospholipid antibodyen
dc.subjectabsence of side effectsen
dc.subjectadulten
dc.subjectanterior eye chamberen
dc.subjectanticoagulant therapyen
dc.subjectantiphospholipid syndromeen
dc.subjectarticleen
dc.subjectcase reporten
dc.subjectclinical assessmenten
dc.subjecteye diseaseen
dc.subjectfemaleen
dc.subjectfluorescence angiographyen
dc.subjectfollow upen
dc.subjecthumanen
dc.subjectischemic optic neuropathyen
dc.subjectmaleen
dc.subjectoptic disken
dc.subjectperipheral occlusive artery diseaseen
dc.subjectretina examinationen
dc.subjectretina macula edemaen
dc.subjectretina vasculitisen
dc.subjectvisual acuityen
dc.subjectvitreous diseaseen
dc.subjectvitritisen
dc.titleOcular disorders as the prevailing manifestations of antiphospholipid syndrome: A case seriesen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής